Stem Cells Archives | Page 183 of 200

Exclusive Interviews with Stem Cell Leaders – Accellta, Gamida Cell, and More

January 11, 2016 By Cade Hildreth, Founder & President Leave a Comment

We just released exclusive question and answer (Q&A) interviews with the CEO and Head of Business Development for Accellta, a revolutionary stem cell culture company. Accellta is introducing a paradigm shift to the stem cell marketplace, announcing that it can quickly, efficiently, and cost-effectively grow massive quantities of clinical grade cells in xeno-free, feeder-free culture using large bioreactors.

With this revolutionary technology, the company has already already secured licensing deals with major players across the stem cell products marketplace, including Thermo Fisher Scientific, STEMCELL Technologies, and Miltenyi Biotec. [Read more…]

$1.3 Billion Buy-Out – Thermo Fisher Scientific to Acquire Affymetrix

January 10, 2016 By Cade Hildreth, Founder & President Leave a Comment

Based in Waltham, Massachusetts, Thermo Fisher Scientific is a behemoth in the area of laboratory research products, featuring a wide range of stem cell product lines. As cited in the press release below, the company announced January 8th, 2016, that it will be acquiring the Affymetrix, a company based in Santa Clara, California, that manufactures DNA microarrays. The move will expand Thermo Fisher Scientific’s portfolio of “premier brands” that include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Service, among many others.

While a purchase price of $1.3 billion sounds like a significant acquisition, Thermo Fisher Scientific has a market capitalization of $56.3 billion and revenues of approximately $17 billion, as well as more than 50,000 employees worldwide. Put into context, this is another in a long line of strategic acquisitions by Thermo Fisher Scientific. [Read more…]

ORIG3N™ Presents At J.P. Morgan/Biotech Showcase And Names New Board Members

January 9, 2016 By Cade Hildreth, Founder & President Leave a Comment

Founded in April 2014, ORIG3N is an interesting and innovative company that is developing the world’s largest uniformly consented blood cell repository, known as LifeCapsule. They are using these blood cells to produce patient-specific induced pluripotent stem cells (iPSCs). The company also has two other business segments, called LifeProfile and LifeSystems. As a newcomer to the biotech industry, there has been a great deal of activity going on at the company, which you can read more about in this fascinating interview with James Lovgren, Chief Business Officer of ORIG3N.

In major news released today, ORIG3N now announced that it will be presenting at the upcomingJ.P. Morgan/Biotech Showcase and named three new board members, Tom Mac Mahon, George Hara, and Justin Xiang. [Read more…]

Why I Respectfully Disagree with Other Market Intelligence Reports about Cord Blood Banking

January 7, 2016 By Cade Hildreth, Founder & President Leave a Comment

Recently, I’ve seen posts on LinkedIn and the web for a cord blood market report titled “Global Cord Blood Banking Services (Stem Cell) Market, Size, Share, Trends, Forecast, Global Analysis, Research, Report, Segmentation, and Future Demand, 2012 – 2020.”

I rarely reflect on products by other companies, but this report is disturbing in that it is painfully inaccurate.

As global business expert Joe Polish likes to say, “The most expensive information is bad information,” and this is a case of that situation.

In the Executive Summary, a highlight of the main findings for this report, Allied Market Research states that the “Cord blood market is expected to grow at 33.5% CAGR from 2012-2020.”
[Read more…]

Need More Rapid Revenue Growth for Your Stem Cell Company or Cord Blood Bank?

January 6, 2016 By Cade Hildreth, Founder & President Leave a Comment

Competing in the rapidly-moving stem cell marketplace is a difficult task. You must analyze market conditions, predict industry trends, and capitalize on market changes before the competition. Especially within the rapidly evolving stem cell marketplace, it can be difficult to make educated, informed decisions that will drive revenue growth for your company, while limiting failed products that will not have demand in the marketplace.

Within an ever-changing marketplace, individuals who commit to understanding current opportunities and threats are positioned for a substantial strategic advantage. [Read more…]